Nuvalent, Inc. Competitors
| Symbol | Share Price | Market Cap | P/E Ratio | Employee Count | Revenue |
|---|---|---|---|---|---|
ACLX
Arcellx, Inc. |
$78.71 | $2.72 B | -49.3 | 130 | $110.32 M |
ASND
Ascendis Pharma A/S |
$137.70 | $7.77 B | -14.19 | 879 | $266.72 M |
CERE
Cerevel Therapeutics Holdings, Inc. |
$44.96 | $7.29 B | -14.66 | 355 | $0 |
CGEM
Cullinan Oncology, Inc. |
$12.41 | $1.29 B | -7.16 | 85 | $0 |
DICE
DICE Therapeutics, Inc. |
$47.55 | $2.27 B | -21.91 | 71 | $0 |
GPCR
Structure Therapeutics Inc. |
$28.26 | $2.47 B | -23.59 | 136 | $0 |
KNSA
Kiniksa Pharmaceuticals, Ltd. |
$19.96 | $1.35 B | 146.62 | 297 | $270.26 M |
PCVX
Vaxcyte, Inc. |
$83.34 | $7.72 B | -16.54 | 254 | $0 |
REPL
Replimune Group, Inc. |
$12.57 | $485.18 M | -2.44 | 331 | $0 |
TVTX
Travere Therapeutics, Inc. |
$18.97 | $542.80 M | -1.32 | 380 | $145.24 M |
UTHR
United Therapeutics Corporation |
$360.21 | $12.20 B | 13.02 | 1168 | $2.33 B |
VRDN
Viridian Therapeutics, Inc. |
$19.76 | $776.72 M | -2.71 | 94 | $314,000 |
VTYX
Ventyx Biosciences, Inc. |
$2.14 | $229.83 M | -1.01 | 75 | $0 |